Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections.
Emergence of antimicrobial resistance is a growing problem and a public health threat. New drugs must be designed with emerging needs in mind: specific resistant and hard-to-treat organisms. But the difficulty to find real new drugs is a major problem. Only the oxazolidinones, the cationic peptides and the lipopeptide antibiotics can be truly regarded as structurally novel drugs, although the peptide deformylase inhibitors and, possibly, the pleuromutilins can be considered a potential advancement in the field. Obviously, these antibiotics must be reserved only to cases of documented ineffectiveness of the common antimicrobial agents.
Department of Respiratory Medicine, Unit of Pneumology and Allergology, A. Cardarelli Hospital, Via del Parco Margherita 24, 80121 Naples, Italy. mcazzola@qubisoft.it
Mario
M
Cazzola
Alessandro
A
Sanduzzi
Maria Gabriella
MG
Matera
D000081:Acetamides / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000581:Amidohydrolases; D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019540:Area Under Curve; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D017850:Economics, Pharmaceutical; D006207:Half-Life; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000626:Aminopeptidases; D000581:Amidohydrolases; C084507:peptide deformylase; D000069349:Linezolid